SCHEMBL1165591

SCHEMBL1165591

Oc1ccc(/C=N/Nc2nc3ccccc3s2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 14/20 0.68
▸ NPC1 O15118 12/20 0.68
▸ RAB9A P51151 11/20 0.68
▸ GAA P10253 11/20 0.65
▸ KMT2A Q03164 11/20 0.65
▸ MEN1 O00255 10/20 0.65
▸ KDM4E B2RXH2 5/20 0.65
▸ MAPK1 P28482 3/20 0.65
▸ SMN1; SMN2 Q16637 9/20 0.61
▸ TP53 P04637 2/20 0.61
▸ NFKB1 P19838 4/20 0.60
▸ NFKB2 Q00653 4/20 0.60
▸ RELA Q04206 4/20 0.60
▸ TDP1 Q9NUW8 4/20 0.60
▸ NPSR1 Q6W5P4 3/20 0.60
▸ POLB P06746 3/20 0.60
▸ PAX8 Q06710 1/20 0.60
▸ LMNA P02545 4/20 0.60
▸ HPGD P15428 2/20 0.56
▸ GLA P06280 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1165592 1.00 MAPT (0.68) MAPTNPC1RAB9AGAAKMT2A
SCHEMBL1231354 0.88 MAPT (0.70) MAPTNPC1RAB9AGAAKMT2A
SCHEMBL1231353 0.88 MAPT (0.70) MAPTNPC1RAB9AGAAKMT2A
SCHEMBL21010612 0.85 MAPT (0.68) MAPTNPC1RAB9AGAAKMT2A
SCHEMBL13779288 0.85 MAPT (0.75) MAPTNPC1RAB9AGAAKMT2A
SCHEMBL10038665 0.84 MAPT (0.65) MAPTNPC1RAB9AGAAKMT2A
SCHEMBL1164674 0.83 MAPT (0.52) MAPTNPC1RAB9AGAAKMT2A
SCHEMBL1164672 0.83 MAPT (0.52) MAPTNPC1RAB9AGAAKMT2A
SCHEMBL28684828 0.83 MAPT (0.61) MAPTNPC1RAB9AGAAKMT2A
SCHEMBL1132583 0.83 MAPT (0.58) MAPTNPC1RAB9AGAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9512066-B2 Enhancers of protein degradation MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) 2016-12-06 — — US disclosed
US-20120282629-A1 Enhancers of Protein Degradation MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) 2012-11-08 — — US disclosed
EP-2488485-A1 ENHANCERS OF PROTEIN DEGRADATION Max-Delbrück-Centrum für Molekulare Medizin (DE) 2012-08-22 — — EP disclosed
WO-2011020883-A9 ENHANCERS OF PROTEIN DEGRADATION Max-Delbrück-Centrum für Molekulare Medizin (DE) 2012-07-12 — — WO disclosed
WO-2011020883-A1 ENHANCERS OF PROTEIN DEGRADATION Max-Delbrück-Centrum für Molekulare Medizin (DE) 2011-02-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120282629-A1 Enhancers of Protein Degradation HTT, HYPK, TFEB MAPT 149/4885NPC1 898/4885RAB9A 2389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback